Brus ★ Spain, 2023-06-06 14:18 (617 d 12:44 ago) Posting: # 23578 Views: 2,577 |
|
Dear all, I have reviewed the RSABE design possibilities according new draft FDA guideline Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA and in accordance with FDA Draft Guidance on Progesterone; regarding RSABE. And it is set out as follow: - Full replicate: 4-ways, 2-sequences: TRTR/RTRT - Partial replicate: 3-ways, 3-sequences: TRR / RTR / RRT But nothing is said about the option full-replicate 3-ways, 2-sequences: TRT / RTR, which does seem to be included in the guideline Statistical Approaches to Establishing Bioequivalence. Does this mean that this design can no longer be used? Thank you so much Best regards, Edit: Guidances linked. [Helmut] |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2023-06-07 12:22 (616 d 14:40 ago) @ Brus Posting: # 23579 Views: 2,103 |
|
Hi Brus, ❝ But nothing is said about the option full-replicate 3-ways, 2-sequences: TRT / RTR,…… The 👨✈️ ❝ … which does seem to be included in the guideline Statistical Approaches to Establishing Bioequivalence. ![]() ❝ Does this mean that this design can no longer be used? — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |